Q3 EPS Estimates for Beam Therapeutics Lowered by Wedbush

Key Points

• Wedbush has revised their Q3 2025 EPS estimate for Beam Therapeutics from ($1.08) to ($1.11), reflecting a negative outlook for the company.
• The consensus estimate for Beam Therapeutics’ full-year earnings stands at ($4.57) per share, with expected losses continuing into 2026.
• Despite the earnings revisions, Beam Therapeutics retains a majority "buy" rating among analysts, with the average target price set at $48.42.

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at Wedbush cut their Q3 2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Tuesday, August 5th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of ($1.11) per share for the quarter, down from their previous forecast of ($1.08). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. Wedbush also issued estimates for Beam Therapeutics' Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.58) EPS, Q1 2026 earnings at ($1.30) EPS, Q2 2026 earnings at ($1.45) EPS, Q3 2026 earnings at ($1.61) EPS, Q4 2026 earnings at ($1.72) EPS, FY2026 earnings at ($6.09) EPS, FY2027 earnings at ($7.38) EPS, FY2028 earnings at ($6.51) EPS and FY2029 earnings at ($2.89) EPS.

A number of other equities analysts have also commented on the stock. Barclays cut their price target on shares of Beam Therapeutics from $25.00 to $21.00 and set an "equal weight" rating on the stock in a report on Wednesday, August 6th. Wells Fargo & Company dropped their target price on shares of Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Cantor Fitzgerald upgraded shares of Beam Therapeutics to a "strong-buy" rating in a report on Monday, July 21st. Finally, Guggenheim dropped their target price on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, nine have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $48.45.

Beam Therapeutics Stock Performance

Shares of NASDAQ:BEAM traded down $0.58 during mid-day trading on Thursday, reaching $17.04. 894,680 shares of the company's stock were exchanged, compared to its average volume of 2,047,350. The firm has a market capitalization of $1.72 billion, a price-to-earnings ratio of -3.79 and a beta of 2.22. The business's fifty day moving average price is $18.84 and its 200-day moving average price is $20.94. Beam Therapeutics has a twelve month low of $13.52 and a twelve month high of $35.25.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.04) by $0.04. The business had revenue of $8.47 million for the quarter, compared to analysts' expectations of $13.29 million. Beam Therapeutics had a negative net margin of 661.31% and a negative return on equity of 43.15%. The firm's quarterly revenue was down 28.0% compared to the same quarter last year. During the same period last year, the firm posted ($1.11) earnings per share.

Insider Buying and Selling at Beam Therapeutics

In other news, insider Fmr Llc sold 48,374 shares of the firm's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $20.50, for a total value of $991,667.00. Following the transaction, the insider directly owned 2,073,665 shares of the company's stock, valued at approximately $42,510,132.50. This trade represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold a total of 49,624 shares of company stock valued at $1,015,628 in the last quarter. 3.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Beam Therapeutics

A number of institutional investors have recently made changes to their positions in BEAM. GF Fund Management CO. LTD. acquired a new position in shares of Beam Therapeutics in the fourth quarter valued at approximately $43,000. Allworth Financial LP grew its holdings in shares of Beam Therapeutics by 7,080.0% in the second quarter. Allworth Financial LP now owns 2,513 shares of the company's stock valued at $43,000 after purchasing an additional 2,478 shares in the last quarter. CWM LLC grew its holdings in shares of Beam Therapeutics by 79.8% in the first quarter. CWM LLC now owns 2,684 shares of the company's stock valued at $52,000 after purchasing an additional 1,191 shares in the last quarter. Sterling Capital Management LLC grew its holdings in shares of Beam Therapeutics by 816.0% in the fourth quarter. Sterling Capital Management LLC now owns 2,409 shares of the company's stock valued at $60,000 after purchasing an additional 2,146 shares in the last quarter. Finally, Amalgamated Bank grew its holdings in shares of Beam Therapeutics by 20.4% in the first quarter. Amalgamated Bank now owns 3,153 shares of the company's stock valued at $62,000 after purchasing an additional 534 shares in the last quarter. 99.68% of the stock is currently owned by institutional investors and hedge funds.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.